



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 1893

SERIAL NUMBER 10/510,585	FILING OR 371(c) DATE 10/08/2004 RULE	CLASS 424	GROUP ART UNIT 1651	ATTORNEY DOCKET NO. 2354 US F
APPLICANTS Debra L. Fleenor, Crowley, TX; Allan Shepard, Forth Worth, TX; Nasreen Jacobson, Forth Worth, TX; Iok-Hou Pang, Grand Prairie, TX; Abbot F. Clark, Arlington, TX;				
** CONTINUING DATA ***** This application is a 371 of PCT/US03/12521 04/18/2003 which claims benefit of 60/376,606 04/30/2002				
** FOREIGN APPLICATIONS ***** none				
Foreign Priority claimed <input type="checkbox"/> yes <input checked="" type="checkbox"/> no 35 USC 119 (a-d) conditions <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after met Verified and Acknowledged <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after met		STATE OR COUNTRY TX	SHEETS DRAWING 3	TOTAL CLAIMS 13
Examiner's Signature <i>[Signature]</i> Initials <i>[Initials]</i>		INDEPENDENT CLAIMS 4		
ADDRESS Alcon Research 6201 South Freeway Fort Worth, TX 76134-2099				
TITLE Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies				
FILING FEE RECEIVED 838	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit	